JPRN-jRCTs031180162招募中1 期
A phase I/II study for VEGFR1/2 Peptide Vaccine in Patients with Recurrent, Progressive and Refractory Brain Tumors
Toda Masahiro0 个研究点目标入组 20 人开始时间: 2019年2月27日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 12age old 至 <= 79age old（—）
- 性别
- All
入选标准
- •1) recurrent, progressive and refractory brain tumors (hemangiopericytoma, hemangioblastoma, meningioma, chordoma, ependymoma) without surgical and radiorogical justification
- •2) announcement of a diagnosis
- •3) HLA-A*2402, A*0201, A*0206, A*0207
- •4) Age between 12 to 79
- •5) Performance status (ECOG) of 0-2
- •6) Over 4 weeks after surgery, irradiation, or chemotherapy.
- •7) Sufficient function of important organs.
- •8) No uncontrollable pleural, peritoneal or cardiac effusion.
- •9) Expected survival time: more than 3 months.
- •10) preventing conception
- •11) Written informed consents are obtained.
排除标准
- •1) Uncontrollable severe infectious diseases.
- •2) Serious concomitant diseases
- •3) Adverse event of NCI-CTC grade 3 or 4.
- •4) Unable to take anything orally over 24 hours.
- •5) Active multiple cancers.
- •6) Myeloproliferative diseases such as MDS and CML.
- •7) After allogeneic hematopoietic stem cell transplantation.
- •8) Active autoimmune diseases.
- •9) Severe drug allergy
- •10) Necessity for administration of steroid or immunosuppressive drugs.
- •11) Pregnancy or lactation. Patients hope pregnancy
- •12) Psychiatric disorders.
- •13) Unhealed injury.
- •14) Judged as inappropriate for this study by doctors.
研究者
相似试验
已完成
不适用
Phase I/II study of VEGFR1/2-derived peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for metastatic colorectal cancer with KRAS genetic mutation as a third-line therapycolorectal cancerJPRN-UMIN000002856Devision of Clinical Oncology, Tohoku University Hospital15
招募中
1 期
VEGFR1/2 Peptide Vaccine in Patients with Recurrent, Progressive and Refractory Brain TumorsRecurrent, Progressive and Refractory Brain Tumors(hemangiopericytoma, hemangioblastoma, WHO grade II or III meningioma, chordoma, ependymoma)JPRN-UMIN000029005Keio university school of medicine20
已完成
1 期
A phase I/II study for peptide vaccine of vascular endothelial growth factor receptor-1/2 in patients with progressive or recurrent glioblastoma.GlioblastomaJPRN-UMIN000005545Department of Neurosurgery, Keio University School of Medicine20
进行中（未招募）
1 期
VEGFR 1/2 peptide vaccine for Neurofibromatosis type 2eurofibromatosis type 2 with progressive schwannomaNeurofibromatosis type 2D016518JPRN-jRCTs031180184Toda Masahiro20
招募中
1 期
A phase I/II study for peptide vaccine of vascular endothelial growth factor receptor-1/2 in patients with progressive schwannoma from Neurofibromatosis type 2eurofibromatosis type 2 with progressive schwannomaJPRN-UMIN000023565Keio university school of medicine10